LCM
JNCE

Laurion Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Laurion Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,000
Closed -$880K – 1938
2017
Q1 		$880K Buy
+40,000
New +$848K 0.01% 767

Other funds holding JNCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Laurion Capital Management's JNCE Position: Q2 2017 in Review

Laurion Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2017, closing a stake of 40,000 shares — an estimated $880K sold.

Laurion Capital Management first reported a position in JNCE in Q1 2017 and held it in 1 quarter. The position peaked at $880K in Q1 2017. 72 funds tracked by Wall St. Rank hold JNCE as of Q2 2017.

  • Laurion Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Laurion Capital Management sold 40,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $880K.
  • Laurion Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Laurion Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $880K in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Laurion Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.